Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of DSIP and Humanin — mechanism, dosing, side effects, legal status, and pricing.
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated in 1977 by Schoenenberger and Monnier from cerebral venous blood of rabbits during electrically induced sleep. It has been studied as a putative sleep and stress modulator, but the evidence base is weak, largely pre-2000, and DSIP is not FDA-approved.
DSIP
Humanin
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
DSIP
Humanin
COA corpus from Disclosed Labs — independently tested batches only.
DSIP
69
COAs
99.4%
Avg purity
14
Labs
Humanin
3
COAs
99.5%
Avg purity
2
Labs
DSIP is among peptides under FDA review for the Category 1 (503A) list; if added, it would require a prescription to be compounded by registered 503A/503B pharmacies — not yet authorized. Humanin remains research-only. In April 2026 the FDA removed 12 peptides from Category 2, which does not place them on the Category 1 list or authorize compounding. The FDA's Pharmacy Compounding Advisory Committee is advisory and meets July 23–24, 2026 to review nominations and make recommendations to the FDA.
Schoenenberger & Monnier first isolated and characterized DSIP in 1977 (PNAS 74(3):1282-6, PMID 265572). Graf & Kastin's 1984 review (Neurosci Biobehav Rev, PMID 6145137) summarized the first decade of work, noting reported effects on sleep, pain, and stress but also substantial inconsistency across labs and species. Schneider-Helmert (Eur Neurol 1986, PMID 3792404) reported sleep normalization in 18 middle-aged and elderly chronic insomniacs given DSIP over one week — small, open, and never replicated at scale. Schneider-Helmert et al. (Dtsch Med Wochenschr 1987, PMID 3582201) explored phase-shifted insomnia. Kovalzon & Strekalova (J Neurochem 2006, PMID 16539679) summarized the field as a 'still unresolved riddle,' noting that no DSIP receptor or gene has been identified. No Phase 3 trials, no FDA approval, no modern controlled replication.
Key references
Hashimoto et al. (2001) discovered humanin through functional screening for neuroprotective factors against amyloid-beta toxicity. Yen et al. characterized the S14G-Humanin analog (HNG) as 1000x more potent. Muzumdar et al. demonstrated that humanin improves insulin sensitivity and reduces visceral fat in animal models. Circulating humanin levels decline with age and correlate inversely with Alzheimer's biomarkers. Cohen et al. showed humanin's role in the GH/IGF-1 axis through IGFBP-3 interaction. No human clinical trials have been conducted — all dosing is extrapolated from preclinical data.
DSIP and Humanin are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs